Table of Contents
Advances in Toxicology
Volume 2014 (2014), Article ID 283749, 12 pages
http://dx.doi.org/10.1155/2014/283749
Research Article

Compound-Specific Toxicities Detected in CFU-GM, Rat Kidney NRK Cells, Rat Bladder RBLAK Cells, and Rat Liver Slices following Batracylin or N-Acetyl Batracylin Exposure

Lab of Investigative Toxicology, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Lab for Cancer Research, Frederick, MD 21702, USA

Received 30 April 2014; Revised 3 July 2014; Accepted 4 August 2014; Published 8 September 2014

Academic Editor: Rosa Busquets

Copyright © 2014 Facundo M. Cutuli and Holger P. Behrsing. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Plowman, K. D. Paull, G. Atassi et al., “Preclinical antitumor activity of batracylin (NSC 320846),” Investigational New Drugs, vol. 6, no. 3, pp. 147–153, 1988. View at Google Scholar · View at Scopus
  2. P. Mucci-LoRusso, L. Polin, M. Bissery et al., “Activity of batracylin (NSC-320846) against solid tumors of mice,” Investigational New Drugs, vol. 7, no. 4, pp. 295–306, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Luo, Y. Ren, T. Chou et al., “A structure-activity relationship study of batracylin analogues,” Pharmaceutical Research, vol. 10, no. 6, pp. 918–923, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. S. K. Meegalla, G. J. Stevens, C. A. McQueen et al., “Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin,” Journal of Medicinal Chemistry, vol. 37, no. 20, pp. 3434–3439, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. V. A. Rao, K. Agama, S. Holbeck, and Y. Pommier, “Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX asa biomarker of DNA damage,” Cancer Research, vol. 67, no. 20, pp. 9971–9979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. El-hawari, M. L. Stoltz, and F. Pallas, Species Differences in the Toxic Response to Batracylin (NSC-320846), American Association for Cancer Research, San Francisco, Calif, USA, 2009.
  7. G. J. Stevens, J. L. Burkey, and C. A. McQueen, “Toxicity of the heterocyclic amine batracylin: investigation of rodent N-acetyltransferase activity and potential contribution of cytochrome P450 3A,” Cell Biology and Toxicology, vol. 16, no. 1, pp. 31–39, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. G. J. Stevens, E. J. Lavoie, and C. A. McQueen, “The role of acetylation in the mutagenicity of the antitumor agent, batracylin,” Carcinogenesis, vol. 17, no. 1, pp. 115–119, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Stevens, M. Payton, E. Sim, and C. A. Mcqueen, “N-acetylation of the heterocyclic amine batracylin by human liver,” Drug Metabolism and Disposition, vol. 27, no. 9, pp. 966–971, 1999. View at Google Scholar · View at Scopus
  10. M. M. Ames, D. A. Mathiesen, and J. M. Reid, “Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat,” Investigational New Drugs, vol. 9, no. 3, pp. 219–225, 1991. View at Google Scholar · View at Scopus
  11. S. G. Gómez, J. A. Bueren, G. Faircloth, and B. Albella, “Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: yondelis(ET-743),” Toxicology in Vitro, vol. 17, no. 5-6, pp. 671–674, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Dal Negro, M. Bonato, and L. Gribaldo, “In vitro bone marrow granulocyte-macrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs,” Cell Biology and Toxicology, vol. 17, no. 2, pp. 95–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. R. E. Parchment, M. Gordon, C. K. Grieshaber, C. Sessa, D. Volpe, and M. Ghielmini, “Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests,” Annals of Oncology, vol. 9, no. 4, pp. 357–364, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Parent-Massin, “Relevance of clonogenic assays in hematotoxicology,” Cell Biology and Toxicology, vol. 17, no. 2, pp. 87–94, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Pessina, B. Albella, M. Bayo et al., “Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics,” Toxicological Sciences, vol. 75, no. 2, pp. 355–367, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Pessina, B. Albella, J. Bueren et al., “Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay,” Toxicology in Vitro, vol. 15, no. 6, pp. 729–740, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Lin and Y. Will, “Evaluation of drugs with specific organ toxicities in organ-specific cell lines,” Toxicological Sciences, vol. 126, no. 1, pp. 114–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. M. Sue, C. Cheng, Y. Chou, C. Chang, P. Lee, and S. Juan, “Ectopic overexpression of haem oxygenase-1 protects kidneys from carboplatin-mediated apoptosis,” British Journal of Pharmacology, vol. 162, no. 8, pp. 1716–1730, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Amin, C. Ip, L. Jimenez, C. Tyson, and H. Behrsing, “In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices,” Toxicological Sciences, vol. 87, no. 2, pp. 442–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Amin, C. Ip, B. Sato et al., “Characterization of ANIT-induced toxicity using precision-cut rat and dog liver slices cultured in a dynamic organ roller system,” Toxicologic Pathology, vol. 34, no. 6, pp. 776–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. P. Behrsing, K. Amin, C. Ip, L. Jimenez, and C. A. Tyson, “In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin in rats,” Toxicology in Vitro, vol. 19, no. 8, pp. 1079–1088, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. H. P. Behrsing, A. E. M. Vickers, and C. A. Tyson, “Extended rat liver slice survival and stability monitored using clinical biomarkers,” Biochemical and Biophysical Research Communications, vol. 312, no. 1, pp. 209–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. E. M. Vickers and R. L. Fisher, “Precision-cut organ slices to investigate target organ injury,” Expert Opinion on Drug Metabolism and Toxicology, vol. 1, no. 4, pp. 687–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Pessina, A. Bonomi, L. Cavicchini et al., “Prevalidation of the rat CFU-GM assay for in vitro toxicology applications,” ATLA Alternatives to Laboratory Animals, vol. 38, no. 2, pp. 105–117, 2010. View at Google Scholar · View at Scopus
  25. Institute for Laboratory Animal Research, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, and National Research Council, Guide for the Care and Use of Laboratory Animals, The National Academies Press, 1996.
  26. G. J. Stevens and C. A. McQueen, “Species variation in the genotoxicity of batracylin,” Toxicology and Applied Pharmacology, vol. 126, no. 1, pp. 39–44, 1994. View at Publisher · View at Google Scholar · View at Scopus